Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals Inc. - Common Stock (NQ:VNDA)

7.950 -0.300 (-3.64%)
Streaming Delayed Price Updated: 1:57 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanda Pharmaceuticals Inc. - Common Stock

In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
What's Going On With Vanda Pharmaceuticals Stock Wednesday? ↗
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA approval of NEREUS for the prevention of vomiting induced by motion. 
Via Benzinga
Here are the top movers in Wednesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2025-12-31: top gainers and losers in today's session. ↗
Via Chartmill
VNDA Stock On Track To Open At Three-Year High – FDA Clears First New Motion Sickness Drug In Decades ↗
Via Stocktwits
Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗
Via Stocktwits
The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell ↗
Via Stocktwits
Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review ↗
Via Stocktwits
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Edge Lower For Final Session Of 2025: Why NVDA, TSLA, VNDA Are On Traders' Radar Today ↗
Investors head into the final trading session of 2025 with caution. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025. 
Via Stocktwits
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
This small-cap drugmaker just soared on positive clinical trial data, but should you jump on the bandwagon? 
Via The Motley Fool
News headline image
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets. 
Via Benzinga
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark ↗
Via Stocktwits
News headline image
Earnings Scheduled For July 31, 2025 ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Top movers in Tuesday's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026. 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
This Trex Company Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) Reports Q3 2025 Earnings Miss on Revenue, Beat on EPS ↗
Vanda Pharma's Q3 2025 results show a revenue miss but a smaller-than-expected loss. The stock fell as strong Fanapt sales growth was offset by investor focus on the top-line shortfall. 
Via Chartmill
Topics Earnings
News headline image
Jim Cramer Calls Cameco A Good Company, Recommends Buying This Financial Stock ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda Pharmaceuticals. 
Via Benzinga
News headline image
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 ↗
AnaptysBio plans to separate into Royalty Management Co. and Biopharma Co. by 2026, with each positioned for growth in distinct market areas. 
Via Benzinga
News headline image
Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals” ↗
The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety. 
Via Stocktwits
Topics Retirement
News headline image
Vanda (VNDA) Q2 Revenue Rises 4% ↗
Via The Motley Fool
Topics Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.